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The efficacy of AmBisome, a liposomal formulation of amphotericin B, was
compared with that of Fungizone (amphotericin B desoxycholate), in a rat model of
unilateral, pulmonary aspergillosis. Repeated administration of cyclophosphamide
resulted in persistent, severe, granulocytopenia. The left lung was inoculated with a
conidial suspension of Aspergillusfumigatus, thus establishing an unilateral infection.
Antifungal treatment was started 40 h after fungal inoculation, at which time
mycclial disease was confirmed by histological examination. Both Fungizone 1 mg/kg
and AmBisome 10 mg/kg resulted in increased survival in terms of delayed as well
as reduced mortality. Quantitative cultures of lung tissue showed that only
AmBisome 10 mg/kg resulted in reduction of the number of fungal cfus in the
inoculated left lung. Compared with Fungizone, both AmBisome 1 mg/kg/day and
AmBisome 10 mg/kg/day significantly prevented dissemination from the infected left
lung to the right lung. In addition, both AmBisome regimens reduced hepatosplenic
dissemination, and the 10 m/kg dosage fully prevented this complication. In
conclusion, when compared with Fungizone, in this model AmBisome is more
effective in reducing dissemination of unilateral, pulmonary aspergillosis, even when
given in relatively low dosage. Such low dosages may have a place in prophylactic
settings.
Introduction
Aspergillus spp. are opportunistic fungi, giving rise to pulmonary and other invasive
infections in immunocompromised patients (Rinaldi, 1983; Gerson et al., 1985; Ruutu
et al., 1987; Denning & Stevens, 1990; McWhinney et al., 1993). The number of invasive
aspergillus infections is steadily increasing (Denning et al., 1991; McWhinney et al.,
1993; Khoo & Denning, 1994). This is due to growing numbers of susceptible patients,
especially those with prolonged granulocytopenia after aggressive chemotherapy.
Despite considerable toxicity amphotericin B is still the most effective agent to treat
these infections. However, the efficacy of this drug is rather disappointing in persistently
granulocytopenic patients in whom mortality rates up to 100% have been observed
(Denning & Stevens, 1990).
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Encapsulated into liposomes amphotericin B has considerably diminished toxicity,
and can be administered in much higher dosages (Lopez-Berestein et al., 1985; Meunier,
Prentice & Ringden, 1991; Proffitt et al., 1991; de Marie, Janknegt &
Bakker-Woudenberg, 1994; Mills et al., 1994). The administration of higher dosages
may result in improved efficacy, as the antifungal activity of amphotericin B is
concentration dependent. We compared the efficacy of amphotericin B deoxycholate
(Fungizone) with that of liposomal amphotericin B (AmBisome) in an animal model
of pulmonary aspergillosis that closely mimics human disease.
Materials and methods
Animals
Female R strain albino rats, which were pathogen free, 18-25 weeks old and weighed
185-235 g (bred at REPGO-TNO, Rijswijk, The Netherlands), were used for all
experiments. Both the control group and each of the three treatment groups consisted
of 15 animals. Animals received a normal, pathogen free diet and water ad libitum.
Induction of granulocytopenia and supportive care
According to a slight modification of the method described by Roosendaal et al. (1991),
persistent granulocytopenia was induced by one dose of cyclophosphamide 90 mg/kg
intraperitoneally five days before fungal inoculation, followed by repeated doses of
cyclophosphamide 60 mg/kg at 1 day before and 3, 7 and 11 days after inoculation. The
doses of cyclophosphamide were adjusted for body weight changes during the
experiment. Before the experiments with amphotericin B this scheme was tested in a
group of six animals. Quantitation of blood leucocytes was done in blood samples
obtained by orbital puncture under light CO2 anaesthesia. Total leucocyte counts were
determined by dilution of these samples in Turk solution in a haemacytometer. Total
numbers of granulocytes were calculated after differential counts of leucocytes in
cytospin preparations of buffy coats.
To prevent bacterial superinfections, strict hygienic care was maintained and animals
received ciprofloxacin (660 mg/L) and polymyxin B (100 mg/L) in their drinking water
during the whole experiment. Starting 1 day before inoculation, daily im amoxycillin
(40 mg/kg/day) was added to this regimen for the remainder of the experiment.
Fungal strain
A strain of Aspergillus fumigatus isolated from an immunocompromised patient with
invasive pulmonary aspergillosis was used. This strain was stored under oil on
Sabouraud dextrose agar (SDA) (Oxoid, Basingstoke, England) slopes during the study.
At least once every two months, the strain was passed through a rat to maintain its
virulence. The MIC and MFC of amphotericin B for this A. fumigatus strain (Schmitt
et al. 1988) were 0.4 and 0.8 mg/L, respectively. There were no differences in MIC and
MFC values if a high inoculum (1 x W conidia/mL) versus a low inoculum (5 x 103
conidia/mL) was used.
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Experimental lung infection
A fumigatus was cultured at 37°C for 96 h on SDA until a dense mycelium with
abundant conidia had formed. These conidia were harvested in 10 mL sterile saline.
Conidia were removed from the thallus by rubbing the colony-surface gently with a glass
pipette. This resulted in a conidial suspension without hyphal elements (confirmed by
microscopy). The suspension was washed twice in sterile phosphate buffered saline
(PBS). Subsequently, conidia were resuspended in sterile PBS (pH 7.4) and counted in
a haemacytometer. In addition, the viability of the conidia was determined by culturing
ten-fold serial dilutions on SDA.
Infection of the left lung was established according to the methods described by
Bakker-Woudenberg, Van den Berg & Michel (1982). Briefly, under general anaesthesia
the left main bronchus was intubated. A cannula was passed through the tube and the
left lobe of the lung was inoculated with 0.02 mL of the conidial suspension. This
resulted in a left-sided pneumonia. Sixty minutes before this procedure animals received
a prophylactic im dose of gentamicin (6 mg/kg) and an extra im dose of amoxycillin
(40 mg/kg).
Antifungal treatment
Amphotericin B deoxycholate (Fungizone, Bristol Myers-Squibb, The Netherlands) and
liposomal amphotericin B (AmBisome, Vestar, San Dimas, CA) were reconstituted and
further diluted in 5% glucose in water. Daily doses were administered iv into the tail
vein over at least 30 sec, in a volume of 1 mL or less. Animals received one of the
following regimens: 1 mg/kg Fungizone, 1 mg/kg AmBisome or 10 mg/kg AmBisome
(these dosages were calculated a priori and not adjusted for weight-changes during the
experiment). A comparison dosage of 10 mg/kg of Fungizone was not investigated as
the LDM of Fungizone in rats is 1.6 mg/kg (Proffitt et al., 1991). Treatment was started
40 h after fungal inoculation, at which time mycelial disease could be confirmed by
histological examination of lung tissue, and was continued for 10 consecutive days.
Toxicity
Our study was not designed to investigate in detail the toxicity associated with the
treatment regimens. However, to check for the occurrence of gross toxicity, renal and
hepatic functions were monitored. Abnormalities of renal function were detected by
measuring serum creatinine and blood urea nitrogen (BUN) after ten days of
administration of Fungizone (1 mg/kg/day and AmBisome lOmg/kg/day. Abnormali-
ties of hepatic function were detected by measuring serum aspartate aminotransferase
(ASAT) and alanine aminotransferase (ALAT).
Therapeutic end points
Several end points were used to evaluate the efficacy of antifungal treatment. Animals
were checked twice every day and mortality was recorded for 12 days after fungal
inoculation. In addition, surviving animals were sacrificed 24 h after the last dose of
antifungal agent to determine the extent of fungal disease present. From all animals that
died or were killed the left and right lung, liver and spleen were aseptically removed
and disrupted in 20 mL distilled water in a homogenizer (The VirTis Co. Inc., Gardiner,
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NY, USA) for 45 sec at 10,000 rpm. Liver and spleen of each rat were homogenized
together. Serial ten-fold dilutions of the homogenates were prepared in distilled water
and 0.2 mL samples of each dilution, as well as 2 mL samples of the undiluted
homogenates, were spread on to SDA plates which were incubated at 37DC for 48 h.
Cfus were counted after 24 and 48 h of incubation. The remainders of the organ
homogenates were poured into SDA plates and incubated at 37°C for 48 h, in order
to count very low numbers of cfus or to prove sterility of the organs.
Statistical analysis
Differences in survival curves were assessed using Wilcoxon two-tailed test of life tables.
This test examines the decrease in survival with time as well as the final percentage of
survival. Differences in proportions of animals with dissemination to the right lung, liver
and/or spleen were examined by Fisher's exact test. Differences in mean log cfu were
examined by Mann-Whitney test. P values <0.05 were considered significant in these
analyses.
Results
Granulocytopenia
The dosaging scheme of cyclophosphamide used was sufficient to keep rats persistently
granulocytopenic (granulocytes < 0.1 x 109/L) from the onset of infection (time zero)
throughout the whole experiment. The numbers of total leucocytes and granulocytes are
shown in Figure 1. Differential counts showed that less than 10% of the leucocytes
consisted of granulocytes.
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Figure 1. Number of total leucocytes ( ) and neurophil granulocytes (...) in the blood of rats (n = 5)
treated intraperitoneally with cyclophosphamide 90 mg/kg at day — 5, and repeated doses of 60 mg/kg on
days - 1 , 3, 7 and 11.
AmBisome for pulmonary aspergillosis 219
100,
8 10 11 121 2 3 4 5 6 7
Time (days)
Figure 2. Survival of granulocytopenic rats after inoculation of the left lung with various inocula of A.
fumigatus conidia; 1 x 102 ( • ) or 1 - I03 ( • ) (n = 5), 1 x 104 (A) o r S x l d " ( ) (n = 8)
Experimental infection
Inoculation of relatively low numbers of conidia (1 x lfPorl x 103) resulted in survival
of all or 80%, respectively, of the animals for at least 12 days. Inoculation of higher
numbers of conidia (1 x 104 or 5 x 10*) resulted in 100% mortality, the first rats dying
2 3 4 6 6 7 8 9 10 11 12
Figure 3. Effect of AmBisome versus Fungizone on survival of granulocytopenic rats inoculated with
1 x 10* A .fumigatus conidia. Groups of 15 animals each received Fungizone 1 mg/kg ( • ) AmBisome I mg/kg
(• ) or AmBisome 10 mg/kg (A) on each of 10 consecutive days. Treatment was started 40 h after fungal
inoculation, at what time mycelial growth was finnly established. Control rats survival is also indicated ( ).
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on day four after fungal inoculation (Figure 2). In all experiments on efficacy of
antifungal treatment an inoculum of 1 x 104 conidia was used. The size of the inoculum
also influenced the time at which histologically proven mycelial disease was observed.
Inocula of 1 x 102, 1 x \0* and 5 x 104 resulted in mycelia disease at ;>48 h, 40 h and
30 h after inoculation, respectively. Histological examination revealed abundant septate
branching hyphae invading blood-vessels and lung tissue. Often gross haemorrhagic
infarctions were macroscopically visible, even at a time when infective lesions were still
small. If left untreated, inoculation with 1 x 104 conidia, initially resulted in a left-sided,
invasive, pulmonary infection. After several days the infection disseminated and A.
fumigatus could be detected in the right lung, liver and spleen.
Comparative efficacies of AmBisome and Fungizone
Following fungal inoculation all untreated rats died (Figure 3). Mortality was observed
starting from day 5 after inoculation; by day 9 all rats had died. AmBisome 1 mg/kg/day
did not influence survival significantly. Both Fungizone 1 mg/kg/day and AmBisome
10 mg/kg/day resulted in increased survival (P = 0.006 and 0.027, respectively) in
terms of delayed as well as reduced mortality. Only 2/15 (13%) rats treated with
Fungizone 1 mg/kg and 4/15 (27%) of those treated with AmBisome 10 mg/kg survived
the study period of 12 days. Survival patterns between the animals treated with these
regimens did not differ significantly (P = 0.75).
The results of the quantitative culture of internal organs are shown in the Table. The
number of cfus found in the left lung was not significantly reduced following treatment
with Fungizone 1 mg/kg/day or AmBisome (1 mg/kg/day). In contrast, treatment with
AmBisome 10 mg/kg/day resulted in a significant reduction of the number of cfus in
the left lung (P = 0.003).
Fungizone 1 mg/kg/day had no effect on the dissemination of the infection to the right
lung, the number of rats with infected right lungs and the number of cfus found in these
lungs being the same as in the untreated animals. Dissemination to the right lung after
treatment with AmBisome both at 1 mg/kg/day and 10 mg/kg/day did not differ
significantly from that occuring in untreated animals. However, both regimens reduced
dissemination to the right lungs when compared with treatment with Fungizone
(P = 0.014). In addition, the numbers of cfus found in the right lung, when
dissemination had occurred, were significantly smaller than those found in untreated
rats (P = 0.0008 and 0.0012, respectively).
All treatment regimens reduced dissemination of the infection to the liver and spleen.
However, only with AmBisome both at 1 and 10 mg/kg/day did these differences reach
statistical significance (P = 0.0017 and 0.0002, respectively). AmBisome 10 mg/kg/day
completely prevented dissemination of infection to these organs. During these
experiments we did not study dissemination to the brains of the rats. However, viable
fungal elements were not found in the brains of any of the untreated animals (n = 10).
Toxicity
Serum creatinine, BUN, ALAT and ASAT concentrations after 10 days of treatment
were not significantly increased (data not shown).
Table. Effects of AmBisome and Fungizone on the dissemination of A. fumigatus in granulocytopenic rats
Treatment
None
Fungizone
AmBisome
AmBisome
1 mg/kg/day
1 mg/kg/day
10 mg/kg/day
%
positive
100
100
100
100
Left lung
median
log,0 cfu
3.7 (1.8—4.3)
3.5 (2.7-3.9)
3.3 (2.6-3.7)
3.1 (1.9-3.9)*
%
positive
80
93
47'
47'
Right lung
median
log,0 cfu
2.5 (1.6-2.5)
2.0 (0-2.5)
0.9 (0.7-2.0)*
1.1 (0-2.3)*
Liver
%
positive
66
27
T
(K
and spleen
median
logio cfu
1.9 (0.7-2.5)
1.4 (0.6-1.7)
0.5 (0-0.9)
0
Note: All animals were challenged with 1 x I04 A. fumigatus conidia in the left lung and followed for up to 12 days.
"P < 0.02 compared with Fungizone treated animals (not significant compared with untreated animals), Fisher's exact
test.
hP < 0.01 compared with untreated animals, Mann-Whitney test.
rP < 0.01 compared with untreated animals. Fisher's exact test.
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Discussion
Currently, amphotericin B deoxycholate (Fungizone) is the drug of choice for treating
invasive pulmonary aspergillosis. Newly developed antifungals should, therefore, be
compared with Fungizone to evaluate their efficacy. Because administration of
Fungizone is associated with a number of side effects, the development of new
antifungals with the same efficacy but less toxicity would be a major step forward.
Liposomal formulations of amphotericin B are proven to be considerably less toxic than
amphotericin B deoxycholate, thus allowing much higher dosages (up to ten-fold)
(Lopez-Berestein et al., 1985; Meunier et al., 1991; Proffitt et al., 1991; Mills et al.,
1994). AmBisome (Vestar, San Dimas, California, USA) is a commercially available
liposomal formulation (small unilamellar vesicles) containing amphotericin B (Proffitt
et al., 1991).
Invasive pulmonary aspergillosis is an opportunistic infection usually diagnosed in
patients who have been treated with corticosteroids and/or chemotherapeutic agents.
In various animal models of aspergillosis corticosteroids are administered (Graybill,
Kaster & Drutz, 1983; Van Cutsen, Van Gerven & Janssen, 1987; Schmitt et al., 1988;
Patterson et al., 1989; Niki et al., 1991; Dixon, Polak & Walsh, 1994). However,
corticosteroids have been reported to cause combined toxicity with amphotericin B
(Graybill et al., 1983; Graybill & Kaster, 1984). To avoid the possible influence of this
combined toxicity on survival rates of animals, in the present study cyclophosphamide
was used to obtain persistent, severe, granulocytopenia. Because with this regimen the
viability of pulmonary macrophages is not affected, we examined the histology of the
left lung at different times after fungal inoculation to ascertain that conidia had
germinated when antifungal treatment was started. It was found that the time to
germination depended on the inoculum size. Antifungal treatment was started when
invasive lesions had already developed, which is comparable with the clinical situation;
most other published models ignore this pathophysiological state. It was observed that
the size of macroscopic lesions did not correlate with the numbers of viable A.fumigatus
cultured from those lungs. Francis et al. (1994) reported similar observations. The
invasion of blood vessels by Aspergillus spp. and the consequent extensive haemorrhagic
infarction of lung tissue might help explain these findings. The left lung of a rat consists
of a single lobe, so hyphal invasion of the vessels of this lung might cause alteration
of the macroscopic aspect of the entire lung at a relatively early stage.
In man pulmonary aspergillosis is often initially detected in one of both lungs. In the
rat, by intubating the left main bronchus we were able to inoculate only the left lung
with conidia of A.fumigatus, which allowed us to study progression of the infection
to the right lung, a phenomenon often seen in clinical situations. Furthermore, this
study allows one to study drug pharmacokinetics in infected lung tissue versus
uninfected lung tissue in the same animal. By intubating the left main bronchus it is
possible to inoculate rats in a standardized manner, as demonstrated by the relatively
small range of days at which untreated animals died. The same observations were made
by Schmitt et al. (1988) who inoculated fungi into the trachea.
The efficacy of antifungal agents in invasive aspergillosis is very much influenced by
the duration of deep granulocytopenia (Denning & Stevens, 1990). In man persistent,
severe granulocytopenia is associated with mortality rates up to 100% despite
treatment with amphotericin B. In the present animal model, rats were
granulocytopenic during the whole experiment to mimic human conditions. The
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mortality rate was dependent on the size of the inoculum. This inoculum-dependent-
mortality was described by Dixon et al. (1989), and might be explained by the ability
of pulmonary macrophages to clear a certain amount of viable conidia from the lung.
By increasing the number of conidia administered it was possible to increase the number
of animals dying as well as to shorten the time to death. The inoculum which resulted
in 100% mortality with the first animals dying at day five, was chosen to study the
efficacy of antifungal treatment. The onset of mortality is of importance in clinical
settings. A delay in the progression of infection which can be achieved by antifungal
treatment will provide additional time to repopulate the patient's bone marrow. From
clinical experience it is known, that bone marrow recovery is a crucial factor predicting
a favorable outcome. In the present model all untreated rats died early. AmBisome
1 mg/kg/day did not significantly influence survival, in contrast, both Fungizone
1 mg/kg/day and AmBisome 10 mg/kg/day increased survival by almost 2 days; both
treatment regimens resulted in the survival of some animals (13% and 27%,
respectively). These percentages are relatively low when compared with those reported
by Francis et al. (1994). We believe this to be largely due to differences between the
respective experimental models; for example, antifungal therapy was started earlier by
Francis et al. (1994) than in our study. The importance of these differences are
underscored by the fact that not all of their control animals died during the study
period. The observations in the present study resemble those found in clinical practice
where, despite antifungal treatment, survival percentages are less than 10—20% in
patients with persistent granulocytopenia.
Clear differences were found in the number of organs which were infected when rats
died or were sacrificed. AmBisome in both the low and the high dosage prevented
dissemination from the infected left lung to the right lung in more than 50% of the
animals, while Fungizone did not prevent such dissemination. These findings were
rather surprising, as van Etten et al. (1995) found, in uninfected mice, that after
administering AmBisome, lung tissue concentrations were lower as compared with levels
achieved after equivalent doses of Fungizone. It is possible that AmBisome is
distributed more directly to the fungal elements and surrounds these (Adler-Moore &
Proffitt, 1993), or, if liposomes are taken up by macrophages, this might alter local
concentration of the drug, possibly resulting in higher concentrations at sites of
infection. Furthermore, the relatively prolonged blood circulation of AmBisome, which
results in increased serum concentrations compared with those obtained after
administration of Fungizone, may help to prevent haematological fungal dissemination
(Proffitt et al., 1991). These results suggest a role for relatively low dosages of
AmBisome in a prophylactic setting. The significant reduction of viable A. fumigatus
after treatment with 10 mg/kg/day AmBisome, in both the infected left lung and the
organs involved in dissemination, may indicate that this regimen prevents progression
of fungal lesions. In clinical settings reduction of the number and size of lesions may
improve success rates, notably in cases when bone marrow recovery occurs.
Both AmBisome regimens significantly reduced hepatosplenic dissemination.
However, only the higher dosage of AmBisome was able to fully prevent this
dissemination. This may be due to the fact that high concentrations of AmBisome
accumulate in these organs (Francis et al., 1994). In the present study mortality did not
seem to directly correlate with the degree of dissemination of infection. This might be
due to the relatively acute and progressive type of pneumonia which was induced.
Respiratory insufficiency resulting from vascular involvement of the left lung, rather
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than dissemination in itself, may thus be the direct cause of death in the present model.
This hypothesis, however, needs to be confirmed.
We conclude that in this rat model AmBisome is more effective than Fungizone in
reducing dissemination of pulmonary aspergillosis. Relatively low dosages of
AmBisome may have a place in prophylactic settings. The optimal treatment dosages
of AmBisome need to be further denned.
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